Will JP Morgan’s AI Advisor Be a Winner?
JPMorgan Chase is rolling out “JPM WealthAI for high-net-worth clients.…
Sell
47
IDNA Quote, Financials, Valuation and Earnings
Last price:
$18.96
Seasonality move
:
9.69%
Day range:
$18.33 - $19.02
52-week range:
$17.26 - $25.80
Dividend yield:
1.17%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
63.7K
Avg. volume:
41.8K
1-year change:
-18.26%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$19.02 | -- | -- | -- | $0.11 | 1.17% | -- |
|
BMED
iShares Health Innovation Active ETF
|
$22.64 | -- | -- | -- | $0.01 | 0% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$152.03 | -- | -- | -- | $1.17 | 0.77% | -- |
|
HQL
abrdn Life Sciences Investors
|
$11.48 | -- | -- | -- | $0.47 | 4.09% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$25.49 | -- | -- | -- | $0.00 | 0% | -- |
|
IBB
iShares Biotechnology ETF
|
$116.96 | -- | -- | -- | $0.12 | 0.33% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 1.264 | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | 1.197 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 1.168 | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | 1.401 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.635 | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | 1.327 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
iShares Genomics Immunology and Healthcare ETF vs. Competitors
-
Which has Higher Returns IDNA or BMED?
iShares Health Innovation Active ETF has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat iShares Health Innovation Active ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- BMEDiShares Health Innovation Active ETF-- -- -- -
What do Analysts Say About IDNA or BMED?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Health Innovation Active ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than iShares Health Innovation Active ETF, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than iShares Health Innovation Active ETF.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 BMEDiShares Health Innovation Active ETF0 0 0 -
Is IDNA or BMED More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 1.170, which suggesting that the stock is 17.01% more volatile than S&P 500. In comparison iShares Health Innovation Active ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IDNA or BMED?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 1.17%. iShares Health Innovation Active ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. iShares Health Innovation Active ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or BMED?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than iShares Health Innovation Active ETF quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than iShares Health Innovation Active ETF's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while iShares Health Innovation Active ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for iShares Health Innovation Active ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- BMEDiShares Health Innovation Active ETF-- -- -- --
-
Which has Higher Returns IDNA or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About IDNA or FBT?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is IDNA or FBT More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 1.170, which suggesting that the stock is 17.01% more volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.744, suggesting its less volatile than the S&P 500 by 25.584%.
-
Which is a Better Dividend Stock IDNA or FBT?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 1.17%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0.77% to investors and pays a quarterly dividend of $1.17 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or FBT?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns IDNA or HQL?
abrdn Life Sciences Investors has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat abrdn Life Sciences Investors's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- HQLabrdn Life Sciences Investors-- -- -- -
What do Analysts Say About IDNA or HQL?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand abrdn Life Sciences Investors has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than abrdn Life Sciences Investors, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than abrdn Life Sciences Investors.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 HQLabrdn Life Sciences Investors0 0 0 -
Is IDNA or HQL More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 1.170, which suggesting that the stock is 17.01% more volatile than S&P 500. In comparison abrdn Life Sciences Investors has a beta of 0.856, suggesting its less volatile than the S&P 500 by 14.431%.
-
Which is a Better Dividend Stock IDNA or HQL?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 1.17%. abrdn Life Sciences Investors offers a yield of 4.09% to investors and pays a quarterly dividend of $0.47 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. abrdn Life Sciences Investors pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or HQL?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than abrdn Life Sciences Investors quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than abrdn Life Sciences Investors's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while abrdn Life Sciences Investors's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for abrdn Life Sciences Investors. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- HQLabrdn Life Sciences Investors-- -- -- --
-
Which has Higher Returns IDNA or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About IDNA or HTEC?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is IDNA or HTEC More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 1.170, which suggesting that the stock is 17.01% more volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.217, suggesting its more volatile than the S&P 500 by 21.702%.
-
Which is a Better Dividend Stock IDNA or HTEC?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 1.17%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or HTEC?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns IDNA or IBB?
iShares Biotechnology ETF has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat iShares Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- IBBiShares Biotechnology ETF-- -- -- -
What do Analysts Say About IDNA or IBB?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than iShares Biotechnology ETF, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than iShares Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 IBBiShares Biotechnology ETF0 0 0 -
Is IDNA or IBB More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 1.170, which suggesting that the stock is 17.01% more volatile than S&P 500. In comparison iShares Biotechnology ETF has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.216%.
-
Which is a Better Dividend Stock IDNA or IBB?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.11 per share corresponding to a yield of 1.17%. iShares Biotechnology ETF offers a yield of 0.33% to investors and pays a quarterly dividend of $0.12 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. iShares Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or IBB?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than iShares Biotechnology ETF quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than iShares Biotechnology ETF's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while iShares Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for iShares Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- IBBiShares Biotechnology ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Is Bloom Energy Stock a Buy, Sell or Hold?
While already interesting as the world moves toward greener energy…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
